Group A | Group B | |
General | ||
No of patients | 58 | 33 |
Age, years (mean±SD) | 55.8±11.6 | 60.2±9.6 |
Female sex, n (%) | 22 (37.9) | 13 (39.3) |
Clinical presentation | ||
Systolic arterial pressure, mm Hg (mean±SD) | 139.6±27.9 | 137.5±27.1 |
Diastolic arterial pressure, mm Hg (mean±SD) | 84±12.4 | 81.3±17.1 |
Mean ventricular rate, beats/min (mean±SD) | 129±24.7 | 124.7±26.7 |
Clinical history | ||
Cardiomyopathy, n (%) | 15 (25.8) | 15 (45.4) |
Ischaemic cardiopathy, n (%) | 6 (10.3) | 4 (12.1) |
Arterial hypertension, n (%) | 29 (50) | 17 (51.5) |
Diabetes, n (%) | 2 (3.4) | 5 (15.1) |
Thyroid diseases, n (%) | 2 (3.4) | 2 (6.1) |
Pharmacological therapy | ||
ACE inhibitors/ARB, n (%) | 19 (32.7) | 10 (30.3) |
β-Blockers, n (%) | 20 (34.4) | 7 (21.2) |
Diuretics, n (%) | 12 (20.6) | 8 (24.2) |
Calcium antagonists, n (%) | 5 (8.6) | 5 (15.1) |
Digoxin, n (%) | None | 3 (9.1) |
Anticoagulants, n (%) | 11 (18.9) | 9 (27.2) |
Platelet inhibitors, n (%) | 13 (22.4) | 4 (12.1) |
Antiarrhytmics | ||
Amiodarone, n (%) | 6 (10.3) | 1 (3.0) |
Propafenone, n (%) | 4 (6.8) | None |
Flecainide, n (%) | 6 (10.3) | None |
ARB, angiotensin II receptor blocker.